BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«Unverricht-Lundborg Syndrome

Below is an extended Unverricht-Lundborg Syndrome research listing. Click here to return to the Unverricht-Lundborg Syndrome main in depth entry.

Recent Publications on Unverricht-Lundborg Syndrome:

Unverricht-Lundborg progressive myoclonus epilepsy in Oman.
We analyzed the clinical, electrophysiologic, and genetic features of...
Direct Link
11th July, 2008
Department of Neurology, Royal Hospital, Muscat, Oman.
Clinical picture of EPM1-Unverricht-Lundborg disease.
Unverricht-Lundborg disease (ULD), progressive myoclonic epilepsy type 1...
Direct Link
23rd May, 2008
Kuopio Epilepsy Center, Department of Neurology, Kuopio University
Molecular background of EPM1-Unverricht-Lundborg disease.
Unverricht-Lundborg disease (EPM1) is an autosomal recessively inherited...
Direct Link
23rd May, 2008
Folkhalsan Institute of Genetics and Neuroscience Center, Biomedicum
The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases.
We report eight cases of genetically proven ULD, with the aim of...
Direct Link
15th April, 2008
Sobell Department of Motor Neuroscience and Movement Disorders, Institute
Substantial thalamostriatal dopaminergic defect in Unverricht-Lundborg disease.
PURPOSE: Unverricht-Lundborg disease (ULD) is currently classified as...
Direct Link
11th October, 2007
Department of Neurology, Turku University Hospital, Turku, Finland.
Levetiracetam in three cases of progressive myoclonus epilepsy.
We present three unrelated cases of genetically confirmed progressive...
Direct Link
19th August, 2007
The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
Seizures, ataxia, and neuronal loss in cystatin B heterozygous mice.
Unverricht-Lundborg disease (EPM1) has been considered to be an...
Direct Link
7th July, 2007
Department of Pharmacology, Centre of Excellence of Molecular and Clinical
A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression.
Unverricht-Lundborg disease (EPM1), the most common progressive myoclonic...
Direct Link
18th May, 2007
Division of Neurophysiology and Epileptology, Neurological Institute C.
Long-term evolution of EEG in Unverricht-Lundborg disease.
PURPOSE: Unverricht-Lundborg disease (ULD) is a progressive myoclonus...
Direct Link
16th May, 2007
Centre for the Diagnosis and Care of Epilepsy, Department of
Hyperostosis frontalis interna as a novel finding in Unverricht-Lundborg disease.
PURPOSE: Unverricht-Lundborg disease (ULD) is currently classified as...
Direct Link
26th April, 2007
Department of Neurology, Turku University Hospital, Kiinamyllynkatu 4-8,
Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients.
Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) is an...
Direct Link
17th March, 2007
Department of Medical Genetics and Neuroscience Center, Folkhalsan
Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease.
PURPOSE: Unverricht-Lundborg disease (ULD) is a progressive myoclonus...
Direct Link
25th January, 2007
Centre Saint Paul-H. Gastaut, Marseille, France.
Protein therapy for Unverricht-Lundborg disease using cystatin B transduction by TAT-PTD. Is it that simple?
In this work we analysed the characteristics of the cell-permeable peptide...
Direct Link
19th January, 2007
Department of Molecular and Medical Genetics, University of Toronto,
Altered tryptophan metabolism in the brain of cystatin B-deficient mice: a model system for progressive myoclonus epilepsy.
PURPOSE: Progressive myoclonus epilepsy of the Unverricht-Lundborg type...
Direct Link
13th December, 2006
Department of Pharmacology, University of Tartu, Tartu, Estonia.
[Unverricht-Lundborg disease (PME1)]
Unverricht-Lundborg disease (ULD) is the purest and least severe type of...
Direct Link
15th November, 2006
Centre Saint-Paul--H.
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional